Cover Kidney News
Volume/Issue:
Volume 13: Issue 2
Page:
12
Publication Date:
01 Feb 2021
Online Publication Date:
05 Feb 2021
  • View in gallery

    Visual Abstract by Divya Bajpai Dr. Divya Bajpai is associate professor, Department of Nephrology, Seth GSMC and KEM Hospital Mumbai

Visual Abstract by Divya Bajpai Dr. Divya Bajpai is associate professor, Department of Nephrology, Seth GSMC and KEM Hospital Mumbai
  • 1.

    Fang L, et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8:e21. doi: 10.1016/S2213-2600(20)30116-8. Erratum in: Lancet Respir Med 2020; 88:e54. doi: 10.1016/S2213-2600(20)30235-6

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Sparks MA, et al. Sound science before quick judgement regarding RAS blockade in COVID-19. Clin J Am Soc Nephrol 2020; 15:714−716. doi: 10.2215/CJN.03530320

  • 3.

    Cohen JB, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med [published online ahead of print January 7, 2021]. doi: 10.1016/S2213-2600(20)30558-0; https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30558-0/fulltext#seccestitle160

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Whiting P, et al. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open 2017; 7:e012674. doi: 10.1136/bmjopen-2016-012674

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Lopes RD, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: A randomized clinical trial. JAMA 2021; 325:254-264. doi:10.1001/jama.2020.25864

    • PubMed
    • Search Google Scholar
    • Export Citation
Editorial Type:
Features

This Is the Way: Randomized Clinical Trial Shows ACEis and ARBs Can Safely Be Continued in Patients with COVID-19

Swapnil Hiremath Swapnil Hiremath, MD, MPH, is associate professor in the Division of Nephrology, Department of Medicine, University of Ottawa, Canada. Matthew A. Sparks, MD, FASN, is Assistant Professor of Medicine, Associate Program Director of Nephrology Fellowship, and Director of Medical Student Research in the Department of Medicine, Duke University, and staff physician for the Durham VA Health System, Durham, NC.

Search for other papers by Swapnil Hiremath in
Current site
Google Scholar
PubMed Close
and
Matthew A. Sparks Swapnil Hiremath, MD, MPH, is associate professor in the Division of Nephrology, Department of Medicine, University of Ottawa, Canada. Matthew A. Sparks, MD, FASN, is Assistant Professor of Medicine, Associate Program Director of Nephrology Fellowship, and Director of Medical Student Research in the Department of Medicine, Duke University, and staff physician for the Durham VA Health System, Durham, NC.

Search for other papers by Matthew A. Sparks in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 13: Issue 2
Publication Date:
01 Feb 2021
Page:
12
Restricted access
Save